Company intelligence / Profile preview
ProPhase BioPharma
Uniondale, New York, United Statesprophaselabs.com ↗
- Ownership
- Public · PRPH
- Development stage
- Other
01
Overview
ProPhase BioPharma is advancing clinical programs including large-scale trials for the antiviral Equivir and preclinical/early clinical investigation of Linebacker LB-1 and LB-2 as small molecule PIM kinase inhibitors for cancer, infection, and neurological diseases. BE-Smart diagnostic test for esophageal cancer is in late-stage validation, with commercial launch expected after regulatory coding is secured (anticipated H2 2024).
- Therapeutic areas
- OncologyInfectious DiseasesNeurology
- Modalities
- Small moleculeDietary supplementDiagnosticGenomics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Dana Farber Cancer Institute (development of LB-1 for cancer co-therapy)Genesis Clinical (diagnostic test stratification for BE-Smart)
Beyond the preview
Go deeper on ProPhase BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProPhase BioPharma.